Meeting News
Meeting News
Advertisement
Susan Bal, MDMeeting News | June 15, 2025
Dr. Susan Bal unpacks the promise of GPRC5D CAR T therapy in relapsed/refractory multiple myeloma.
View More
Sabrina AhleMarginal Zone Lymphoma | June 14, 2025
Mosun SC shows positive ORR and CMR rates in first-line MZL, offering an effective, outpatient-friendly treatment option.
Robert ZadottiAcute Myeloid Leukemia | June 14, 2025
Ziftomenib shows strong, lasting responses in R/R NPM1-mutant AML, according to KOMET-001 data shared at EHA 2025.
Robert ZadottiAcute Lymphoblastic Leukemia | June 14, 2025
Brexu-cel shows a significant 5-year OS rate in R/R B-ALL patients, with survival benefits across key subgroups in ZUMA-3.
Robert ZadottiMeeting News | June 14, 2025
Elotuzumab added to KRd shows a favorable trend in 3-year PFS for NDMM patients, EHA 2025 study finds.
Izzah NawazMeeting News | June 14, 2025
Talquetamab remains effective in tough-to-treat myeloma—even when patients develop immune responses.
Sabrina AhleAcute Myeloid Leukemia | June 13, 2025
Talazoparib plus GO shows early signs of activity in relapsed/refractory AML, warranting further study, per EHA 2025 poster.
Sabrina AhleAggressive B-Cell Lymphoma | June 13, 2025
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.
Izzah NawazFollicular Lymphoma | June 13, 2025
Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system.
Melissa BadamoMyeloma | June 13, 2025
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
Melissa BadamoMyeloma | June 12, 2025
Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma.
Izzah NawazMyeloma | June 11, 2025
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Izzah NawazMeeting News | June 11, 2025
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Izzah NawazMeeting News | June 11, 2025
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
Andrew MorenoMeeting News | June 11, 2025
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
Melissa BadamoMyeloma | June 10, 2025
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
Blood Cancers Today Staff WritersMeeting News | June 9, 2025
AI is revolutionizing oncology with faster analysis, better predictions, and more personalized cancer care.
Ruben A. Mesa, MDMyeloproliferative Neoplasms | June 6, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Andrew MorenoMeeting News | June 5, 2025
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Robert ZadottiMantle Cell Lymphoma | June 5, 2025
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
Advertisement
Advertisement